Company intelligence / Profile preview

Neuropathix, Inc.

Doylestown, Pennsylvania, USAneuropathix.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Received a $2.97 million Phase 2 STTR Study Grant from NINDS/NIH to complete preclinical studies for KLS-13019 in CIPN and prepare for FDA Phase 1 Human Clinical Trials

Therapeutic areas
GastroenterologyDermatologyNeurology
Modalities
Small moleculesCannabinoid-inspired moleculesNew Chemical Entities (NCEs)
Industry
Biotech
02

Drug pipeline

5 assets

KLS-13023

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neuropathix, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuropathix, Inc..

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call